JMP Securities analyst Roy Buchanan reiterated a Buy rating on Enanta Pharmaceuticals (ENTA – Research Report) today and set a price target of $103.00. The company's shares closed last Friday at $54.35. According to TipRanks.com, Buchanan is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -18.0% and a 23.4% success rate. Buchanan covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma, Hookipa Pharma, and PolyPid. Currently, the analyst consensus on Enanta Pharmaceuticals is a Moderate Buy with an average price target of $69.89, a 39.8% upside from current levels.
https://www.tipranks.com/news/blurbs/jmp-securities-reiterates-their-buy-rating-on-enanta-pharmaceuticals-enta-2?utm_source=advfn.com&utm_medium=referral
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Feb 2023 to Mar 2023 Click Here for more Enanta Pharmaceuticals Charts.
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Mar 2022 to Mar 2023 Click Here for more Enanta Pharmaceuticals Charts.